<DOC>
	<DOC>NCT00107718</DOC>
	<brief_summary>This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.</brief_summary>
	<brief_title>Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Inclusion criteria: Patients must have melanoma that has spread beyond the original location and has not yet been treated. Tissue from the spreading melanoma should have been tested to confirm it is melanoma. Exclusion criteria: Patients having hepatitis or HIV infection. Taking corticosteroids. Patients with the primary site being occular melanoma or patients with melanoma of the brain.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>IL-18</keyword>
	<keyword>Phase 2</keyword>
	<keyword>melanoma</keyword>
	<keyword>treatment naive</keyword>
</DOC>